Argenx Projects $4B in 2026 R&D and SG&A Expenses, Eyes Up to Five 2027 U.S. Launches

Your call?🐂 Bullish🐻 Bearish

$4B

2026 R&D, SG&A

The 2026 estimate includes transaction-related costs for Forte Biosciences, while a possible empasiprubart launch depends on December trial results.